Anti-angiogenesis in cancer therapy

Related Experiment Video

Updated: Aug 6, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Paula M Muehlbauer1

  • 1Clinical Center Nursing Department, National Institutes of Health, Bethesda, MD, USA.

Seminars in Oncology Nursing
|September 10, 2003
PubMed
Abstract

Insights

This review explores tumor angiogenesis, a key process in cancer development. It identifies targets for anti-angiogenic cancer therapy and discusses agents currently in clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Tumor angiogenesis is the process of new blood vessel formation that supports tumor growth and metastasis.
  • Understanding tumor angiogenesis is crucial for developing effective cancer treatments.
  • This process involves complex molecular signaling pathways that can be targeted therapeutically.

Purpose of the Study:

  • To review the process of tumor angiogenesis.
  • To identify potential molecular targets for anti-angiogenic cancer therapy.
  • To highlight anti-angiogenic agents currently undergoing clinical evaluation.

Main Methods:

  • Literature review of research articles, abstracts, review articles, and book chapters.
  • Synthesis of information on tumor angiogenesis mechanisms.
  • Analysis of data from ongoing clinical trials of anti-angiogenic agents.

Main Results:

  • Tumor angiogenesis is a critical, multistep process essential for tumor survival and growth.
  • Several molecular targets within the angiogenic pathway have been identified for therapeutic intervention.
  • Various anti-angiogenic agents are in different phases of clinical trials, showing promise in cancer treatment.

Conclusions:

  • Targeting tumor angiogenesis offers a viable strategy for antineoplastic therapy by disrupting tumor neovasculature.
  • Ongoing clinical trials are evaluating the efficacy and application of novel anti-angiogenic agents.
  • Oncology nurses require updated knowledge to effectively educate and care for patients receiving these targeted therapies.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.